AccessibilityHelpAbout Us
Kuros Biosciences Ag logo

Kuros Biosciences Ag(OTC) CSBTF

Market Cap$952.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+7,642%
5 Year+796%
1 Year-19%
1 Month-11%
$24.00
+9.09%
+2.00Today
Kuros Biosciences Ag last closing stock price
MetricPriceDate
Last closeUSD 24.002026-09-18
Kuros Biosciences Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 24.002026-09-08
1 month-11.08%USD 26.992026-08-18
3 month-7.69%USD 26.002026-06-18
Year to date-37.4%USD 38.342025-12-30
1 year-19.46%USD 29.802025-09-16
3 year+1,026.76%USD 2.132023-09-07
5 year+795.52%USD 2.682021-09-03
Since inception+7,641.94%USD 0.312016-03-29

Kuros Biosciences Ag Financials at a Glance

Market Cap

$952.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 245.53M

Net Income (TTM)

CHF 1.58M

EPS (TTM)

$0.22

P/E Ratio

105.17

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Price

$24.00

Volume

45

Open

$24.00

Previous Close

$24.00

Daily Range

$24.00 - $24.00

52-Week Range

$22.00 - $42.81

Estimated Earnings Date

Mar 17, 2027

CSBTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kuros Biosciences Ag

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapeutic solutions for tissue repair and bone regeneration. The company operates globally, with a diverse portfolio that includes medical devices and pharmaceuticals aimed at enhancing patient outcomes in various medical fields.

Products and Services
  • MagnetOs Granules and Putty for orthopedic and dental applications
  • KUR-111 and KUR-113 for bone healing, currently in clinical trials
  • Neuroseal, a synthetic tissue sealant for surgical procedures
Growth Outlook
  • Recent quarterly revenue reached CHF 72.3 million, indicating strong market demand
  • Successful completion of Phase 2b trials for KUR-111 and KUR-113 enhances future revenue potential
  • Strategic partnerships, such as with Checkmate Pharmaceuticals, may drive innovation and growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of CHF 66 million reflects a solid growth trajectory
  • Operating income margin improved to 5.6% in the latest quarter
  • Cash and cash equivalents totaled CHF 7.8 million, supporting ongoing operations
Kuros Biosciences AG is positioned to capitalize on the growing demand for advanced medical solutions in tissue repair and bone regeneration. The company's innovative product offerings, combined with a robust pipeline of clinical trials, suggest a promising future. Recent financial performance indicates a positive trend, with increasing revenues and improving margins. The strategic partnerships and ongoing research initiatives further enhance the potential for growth, making Kuros Biosciences AG an intriguing option for investors interested in the biotechnology sector.
AI Generated • Sep 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

178

CEO

Christopher T. Fair

Website

kurosbio.com

Headquarters

Schlieren, ZH 8952, CH

CSBTF Financials

Key Financial Metrics (TTM)

Gross Margin

85.28%

Operating Margin

6.01%

Net Income Margin

5.13%

Return on Equity

10.24%

Return on Capital

10.73%

Return on Assets

5.92%

Earnings Yield

0.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$952.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

39.67M

Volume

45

Avg. Volume

255.656

Financials (TTM)

Gross Profit

CHF 207.97M

Operating Income

CHF 7.38M

EBITDA

CHF 15.05M

Operating Cash Flow

CHF 499.59K

Capital Expenditure

-CHF 7.87M

Free Cash Flow

-CHF 7.37M

Cash & ST Invst.

CHF 7.81M

Total Debt

CHF 10.95M

Kuros Biosciences Ag Performance Analysis

Kuros Biosciences Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 18,832,22424.6%
20232023-12-31CHF 37,349,28598.3%
20242024-12-31CHF 85,159,000128.0%
20252025-12-31CHF 146,058,00071.5%
Kuros Biosciences Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3137.3%
Q22025-06-3045.2%
Q42025-12-314.1%
Q22026-06-309.4%
Kuros Biosciences Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -0.4579.2%
20232023-12-31CHF -0.42-7.4%
20242024-12-31CHF -0.13-68.9%
20252025-12-31CHF 0.06N/A
Kuros Biosciences Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-1552.6%
Q22025-06-3046.3%
Q42025-12-31288.1%
Q22026-06-30-7.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 72.26M

+126.9%

Gross Profit

CHF 61.57M

+117.1%

Gross Margin

85.21%

N/A

Market Cap

$952.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.35M

N/A

Employees

178

N/A

Net Income

CHF 3.45M

+1733.5%

EBITDA

CHF 5.80M

+1368.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 7.81M

-45.3%

Total Debt

CHF 10.95M

+457.4%

Accounts Receivable

CHF 35.65M

+289.4%

Inventory

CHF 21.14M

+208.5%

Long Term Debt

CHF 9.31M

+585.1%

Short Term Debt

CHF 1.64M

+170.5%

Return on Assets

5.92%

N/A

Return on Invested Capital

9.89%

N/A

Free Cash Flow

-CHF 7.48M

-719.8%

Operating Cash Flow

-CHF 2.22M

-604.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNBIFSanBio Company Limited
$16.45+0.00%
NPPNYNippon Shinyaku Co., Ltd.
$5.46+0.00%
PHMMFPharma Mar, S.A.
$94.60+0.00%
MEOBFMesoblast Limited
$1.90+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GRMLGreenland Mines
$16.17+71.67%
NOKNokia
$10.54-3.70%
SOFISoFi Technologies
$17.21+1.41%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.29-4.60%

Questions About CSBTF

What is the current price of Kuros Biosciences Ag?

Kuros Biosciences Ag is trading at $24.00 per share.

What is the 52-week range for Kuros Biosciences Ag?

Over the past 52 weeks, Kuros Biosciences Ag has traded between $22.00 and $42.81.

How much debt does Kuros Biosciences Ag have?

As of the most recent reporting period, Kuros Biosciences Ag reported total debt of CHF 4.97M.

How much cash does Kuros Biosciences Ag have on hand?

Kuros Biosciences Ag reported CHF 19.77M in cash and cash equivalents in its most recent financial results.

What is Kuros Biosciences Ag’s dividend yield?

Kuros Biosciences Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services